BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Biraro IA, Egesa M, Kimuda S, Smith SG, Toulza F, Levin J, Joloba M, Katamba A, Cose S, Dockrell HM, Elliott AM. Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. BMC Infect Dis 2015;15:438. [PMID: 26493989 DOI: 10.1186/s12879-015-1201-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Giraud-Gatineau A, Coya JM, Maure A, Biton A, Thomson M, Bernard EM, Marrec J, Gutierrez MG, Larrouy-Maumus G, Brosch R, Gicquel B, Tailleux L. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection. Elife 2020;9:e55692. [PMID: 32369020 DOI: 10.7554/eLife.55692] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 9.5] [Reference Citation Analysis]
2 Goscé L, Bitencourt J, Gupta R, Arruda S, Rodrigues L, Abubakar I. BCG vaccination following latent TB treatment: Possible implications for different settings. International Journal of Infectious Diseases 2019;80:S17-9. [DOI: 10.1016/j.ijid.2019.02.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Foster M, Hill PC, Setiabudiawan TP, Koeken VACM, Alisjahbana B, van Crevel R. BCG-induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for next-generation vaccines. Immunol Rev 2021;301:122-44. [PMID: 33709421 DOI: 10.1111/imr.12965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Mattos AM, Chaves AS, Franken KL, Figueiredo BB, Ferreira AP, Ottenhoff TH, Teixeira HC. Detection of IgG1 antibodies against Mycobacterium tuberculosis DosR and Rpf antigens in tuberculosis patients before and after chemotherapy. Tuberculosis (Edinb) 2016;96:65-70. [PMID: 26786656 DOI: 10.1016/j.tube.2015.11.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
5 Park HE, Lee W, Shin MK, Shin SJ. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis? Front Immunol 2021;12:703060. [PMID: 34262571 DOI: 10.3389/fimmu.2021.703060] [Reference Citation Analysis]
6 Huaman MA, Ticona E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, Rondan PL, Henson D, Ticona C, Sterling TR, Fichtenbaum CJ, Garvy BA. The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction. Clin Infect Dis 2018;66:886-92. [PMID: 29069328 DOI: 10.1093/cid/cix910] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
7 Kwan PKW, Periaswamy B, De Sessions PF, Lin W, Molton JS, Naftalin CM, Naim ANM, Hibberd ML, Paton NI. A blood RNA transcript signature for TB exposure in household contacts. BMC Infect Dis 2020;20:403. [PMID: 32517725 DOI: 10.1186/s12879-020-05116-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Nakanjako D, Zalwango F, Wairagala P, Luboga F, Andia Biraro I, Bukirwa VD, Mboowa MG, Cose S, Seeley J, Elliott A. Career development for infection and immunity research in Uganda: a decade of experience from the Makerere University – Uganda Virus Research Institute research and training programme. AAS Open Res 2020;3:26. [DOI: 10.12688/aasopenres.13066.1] [Reference Citation Analysis]
9 Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, Skidmore B, Moher D, Alvarez GG. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis 2017;17:265. [PMID: 28399802 DOI: 10.1186/s12879-017-2377-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
10 Nakanjako D, Zalwango F, Wairagala P, Luboga F, Andia Biraro I, Bukirwa VD, Mboowa MG, Cose S, Seeley J, Elliott A. Career development for infection and immunity research in Uganda: a decade of experience from the Makerere University - Uganda Virus Research Institute research and training programme. AAS Open Res 2020;3:26. [PMID: 32734140 DOI: 10.12688/aasopenres.13066.2] [Reference Citation Analysis]
11 Nalwoga A, Webb EL, Chihota B, Miley W, Walusimbi B, Nassuuna J, Sanya RE, Nkurunungi G, Labo N, Elliott AM, Cose S, Whitby D, Newton R. Kaposi's sarcoma-associated herpesvirus seropositivity is associated with parasite infections in Ugandan fishing communities on Lake Victoria islands. PLoS Negl Trop Dis 2019;13:e0007776. [PMID: 31618208 DOI: 10.1371/journal.pntd.0007776] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Delogu G, Vanini V, Cuzzi G, Chiacchio T, De Maio F, Battah B, Pinnetti C, Sampaolesi A, Antinori A, Goletti D. Lack of Response to HBHA in HIV-Infected Patients with Latent Tuberculosis Infection. Scand J Immunol 2016;84:344-52. [PMID: 27636597 DOI: 10.1111/sji.12493] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
13 Michelsen SW, Soborg B, Agger EM, Diaz LJ, Hoff ST, Koch A, Sorensen HCF, Andersen P, Wohlfahrt J, Melbye M. Host immunity to Mycobacterium tuberculosis and risk of tuberculosis: A longitudinal study among Greenlanders. Vaccine 2016;34:5975-83. [DOI: 10.1016/j.vaccine.2016.09.047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Kimuda SG, Andia-Biraro I, Egesa M, Bagaya BS, Raynes JG, Levin J, Elliott AM, Cose S. Use of QuantiFERON®-TB Gold in-tube culture supernatants for measurement of antibody responses. PLoS One 2017;12:e0188396. [PMID: 29161328 DOI: 10.1371/journal.pone.0188396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
15 Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, Galiwango R, Mutonyi G, Vermaak S, Satti I, Verweij J, Tukahebwa E, Cose S, Levin J, Kaleebu P, Elliott AM, McShane H. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial. PLoS Negl Trop Dis 2017;11:e0005440. [PMID: 28472067 DOI: 10.1371/journal.pntd.0005440] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
16 Negi S, Pahari S, Bashir H, Agrewala JN. Intestinal microbiota disruption limits the isoniazid mediated clearance of Mycobacterium tuberculosis in mice. Eur J Immunol 2020;50:1976-87. [PMID: 32673409 DOI: 10.1002/eji.202048556] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]